07:00 , Oct 16, 2006 |  BioCentury  |  Strategy

Pharma goes a courtin'

Increasing competition for late stage clinical assets is forcing the pharmaceutical industry to reach out to the venture capital community as a source of deals, sending a clear message that the market is open for...
07:00 , May 15, 2006 |  BioCentury  |  Strategy

The big & small of it all

Fewer and fewer companies believe they can afford to focus only on small molecules or large molecules. Biogen Idec Inc. recently announced its first venture into the world of small molecule cancer therapeutics, while Merck...
07:00 , Jul 12, 2004 |  BioCentury  |  Strategy

Merck's small company epiphany

Not so long ago, Merck & Co. Inc. was pharma's poster child for not-invented-here syndrome. But of late, the company has been engaged in one of the more aggressive bouts of preclinical and discovery stage...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

Early bird deal

Amid the clamor about pharmaceutical companies scouring under rocks to find late-stage products, it's also been increasingly clear that they haven't abandoned early stage deals as the Phase III cupboard gets bare. Of the 52...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

Whetting pharma's appetite

Early Bird Dealmaking Whetting pharma's appetite Though deals for late stage products promise a more timely impact on earnings, the need for innovation remains urgent for pharma licensing specialists, who say they are willing to...